Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and TherapyReport as inadecuate

Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy - Download this document for free, or read online. Document in PDF available to download.

Mediators of InflammationVolume 2009 2009, Article ID 831670, 8 pages

Review Article2nd Department of Internal Medicine, Medical School of Athens University, Hippokration General Hospital, 115 27 Athens, Greece

Received 5 January 2009; Accepted 6 April 2009

Academic Editor: Fulvio D'Acquisto

Copyright © 2009 Emmanuel A. Tsochatzis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Nonalcoholic fatty liver disease NAFLD is the hepatic manifestation of the metabolic syndrome and can vary from benign steatosis to end-stage liver disease. The pathogenesis of non-alcoholic steatohepatitis NASH is currently thought to involve a multiple-hit process with the first hit being the accumulation of liver fat which is followed by the development of necroinflammation and fibrosis. There is mounting evidence that cytokines secreted from adipose tissue, namely, adipokines, are implicated in the pathogenesis and progression of NAFLD. In the current review, we explore the role of these adipokines, particularly leptin, adiponectin, resistin, tumor necrosis factor-a, and interleukin-6 in NASH, as elucidated in experimental models and clinical practice. We also comment on their potential use as noninvasive markers for differentiating simple fatty liver from NASH as well as on their potential future therapeutic role in patients with NASH.

Author: Emmanuel A. Tsochatzis, George V. Papatheodoridis, and Athanasios J. Archimandritis



Related documents